A medication commonly used to treat overactive bladders significantly reduced hot flashes in men receiving hormone therapy for prostate cancer. Hot flashes affect an estimated 60% to 80% of men receiving androgen-deprivation therapy, and can interfere with sleep, mood and overall well-being. “Hot flashes are often underestimated in men, but they can have a real and lasting impact on quality of life during prostate cancer treatment,” says study first author and Mayo Clinic radiation oncologist Dr Bradley Stish. Men who received the higher dose of oxybutynin experienced the greatest benefit, with an average reduction of nearly seven hot flashes per day, compared with about two fewer hot flashes per day in the placebo group. Oxybutynin has previously been shown to reduce hot flashes in women, but evidence in men had been limited.

Source: The Star March 21, 2026 19:31 UTC